Current and potential PI3K and BTK inhibitors for CLL
What is the role for idelalisib and duvelisib in CLL?
How does an understanding of the microenvironment aid research in CLL?
Combining ublituximab with the novel PI3K inhibitor TGR-1202 for CLL
Factors to consider in frontline and relapsed CLL before treatment